Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

NanoViricides

Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides Inc (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy. Savin gives an overview of what the company does, as well as its current operations and its financial situation. He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 13, 2023 08:31 AM Eastern Daylight Time

Video

Symbiome Partners with THG Ingenuity to Scale E-Commerce Offerings

Symbiome

Symbiome, a leading microbiome-nourishing skincare company, has announced a partnership with THG Ingenuity – an end-to-end direct-to-consumer (DTC) partner of choice for brands looking to connect with consumers through a multichannel commerce approach. The collaboration will focus on leveraging THG’s extensive reach to expand Symbiome’s offering globally. “Right now, nearly all our customers are in America. THG’s global footprint, and end-to-end platform, will allow us to seamlessly fulfill into Europe, the Middle East, and throughout the South-East Asian region,” said Adam Klausner, Symbiome’s Chief Operating Officer. According to Lane Barrocas, THG’s Vice President of eCommerce for North America, THG is experiencing a significant uptick of interest by consumers shopping for science-based skincare, particularly in the microbiome vertical. “Our partnership with Symbiome will allow them to quickly, efficiently and profitably grow and scale their DTC business, while helping to build brand awareness and creating a halo-effect, as they expand into other points of distribution within the market.” About Symbiome Symbiome is a San Francisco-based microbiome biotechnology company focusing on health and wellness. They are the developers of the Symbiome ® brand of BioIntact ® fermented skincare products that nourish and protect the skin and its microbiome, restoring what our skin has lost in the modern world. Symbiome has sponsored three international academic research expeditions deep into the Amazon rainforest, defining an evolutionary reference for the microbiome and transforming our understanding of the healthy human microbiome. Symbiome scientists have translated this groundbreaking research into a line of unique, proprietary skincare products formulated with naturally fermented, Amazonian botanicals. The brand's skincare lineup includes ten clean, organic, sustainable, and traceable products — each with less than eight ingredients. Learn more about Symbiome, and follow Symbiome on Instagram, LinkedIn and Facebook. About THG Ingenuity THG Ingenuity is a unified commerce platform with full stack technology, digital and operations omnichannel capabilities, parented by THG Holdings plc, a vertically integrated, digital-first consumer brands group, retailing its own brands plus third-party brands, via its e-commerce technology, infrastructure, and brand-building expertise. Contact Details BPCM Ali Taekman ali@bpcm.com Company Website https://www.symbiome.com

July 12, 2023 09:30 AM Eastern Daylight Time

Image

Revenue Increased 72% In Q1 2023 For Premier Packaging Corporation, A DSS, Inc. (NYSE: DSS) Wholly Owned Subsidiary

DSS, Inc.

By David Willey, Benzinga DSS, Inc. (NYSE American: DSS), a multinational company operating through strategic acquisitions and business development, released its financial results for the first quarter of 2023. The company, which operates nine business divisions and 40 subsidiaries, reported a significant reduction in operating losses and continued operations optimization. The quarter’s biggest news, however, came from DSS’s most established business segment– product packaging. The company’s Premier Packaging unit saw a 72% revenue increase compared to the same period in 2022. The increase was likely largely a result of the company’s capital investment in state-of-the-art equipment and facilities which expanded capacity and enhanced operational efficiency. With these revenue results, DSS looks to be positioning itself and its wholly-owned subsidiary, Premier Packaging Corporation, in a sector with growth potential. The global packaging and protective packaging market was worth $1 trillion in 2021 and is predicted to reach $1.5 trillion by 2031, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period. Other companies in the printing and distribution sector include Shapeway Holdings Inc. (NYSE: SHPW) and Ennis Inc. (NYSE: EBF). Significantly for Premier Packaging is the packaging industry’s migration from plastics to fiber packaging, which is 100% of Premier’s product mix. The company seems to be benefiting from huge market demand for highly decorative and branded secondary packaging– a key strength in Premier’s business plan. The company reports that its top-tier solutions provide a comprehensive packaging service, and its scalable model means it can fulfill any size order from any size company. Read more about DSS’s Premier Packaging solution here. Zacks SCR Analyst Predicts DSS Stock Price Has Potential To Increase By A Triple-Digit Percentage In its Q1 financial report, DSS also announced that operational loss decreased by 24% for Q1 of 2023 vs. Q1 of 2022. Total costs and expenses had also been reduced by 16% year-over-year (YoY), and net cash increased by investment activity by 115% YoY. Following the Q1 financial statement, a report was issued by Zacks Small Cap Research (SCR), a division of Zacks Investment Research. Zacks estimates that DSS’s stock price has the potential to increase from its present value of $0.37 (as of 7/7/23) to $1.50. Zacks SCR credits DSS’s growth into a multi-industry company with its strong record of opportune acquisitions. In its research report, the analyst also highlighted the strong revenue performance of Premier Packaging Corporation, as well as an upcoming biopharma spin-off which should raise $30 to $50 million through its initial public offering (IPO). DSS is preparing for the spin-off of biopharma Impact BioMedical, where a successful spin-off could result in growth for the company as a whole. DSS’s goals for 2023 involve doubling down on its positive results from the Q1 report. The company is maintaining a key strategic focus on ramping up revenue and customer diversification in the Premier Packaging division. Subsequent to the 1Q report, DSS has also announced the spinoff of its Impact BioMedical subsidiary to DSS shareholders, highlighting DSS’s innovative business plan of periodically distributing stock dividends to its shareholders. Jason Grady, COO of DSS, said, “We continue to execute our business plan of incubating promising businesses to build shareholder value, either through the distribution of a stock dividend in a spinoff or adding a separately traded equity to our balance sheet.” DSS, Inc. appears to have the potential to reward investors with improving fundamentals at the current low market valuation and the beginning of a stock dividend plan as subsidiaries are prepared for eventual spinoff to DSS shareholders. Learn more about what DSS, Inc. is doing to support and spin off businesses. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

July 12, 2023 09:00 AM Eastern Daylight Time

Mechelle Evans Announces GlowByMe, Her New Skincare Company

Client Valley

Las Vegas, NV - Mechelle Evans, the founder of GLO by ME SKIN, is pleased to announce her new company dedicated to revolutionizing the skincare industry. With a focus on providing excellent services and education, Mechelle is transforming the way individuals care for their skin. Mechelle, an esteemed Aesthetician, believes that healthy and glowing skin is a birthright for everyone. Recognizing the skin as the body's largest organ, she emphasizes the importance of proper skincare. Through a comprehensive range of services, Mechelle helps her clients achieve their skin goals, whether it's combating acne, reducing wrinkles, or maintaining overall skin health. However, Mechelle's mission extends beyond offering services; she is dedicated to educating individuals about the significance of skincare. She emphasizes the harmful effects of UV rays and environmental pollutants on the skin, which can lead to premature aging and other skin conditions. By instilling the importance of regular facials, proper cleansing, and the use of high-quality products, Mechelle empowers her clients to protect and enhance their skin's health. Mechelle's journey into skincare began in the early 1990s when she worked as a television extra. Witnessing the damage caused by heavy makeup and sun exposure, she became determined to maintain her own skin's health. Her introduction to Dr. Obagi, a renowned skincare expert, solidified her belief in the transformative power of skincare, prompting her to further educate herself on the subject. Motivated by her passion for helping others achieve clear and healthy skin, Mechelle made the life-changing decision to become a full-time aesthetician. Despite leaving behind a six-figure salary, she was driven by a greater purpose. Mechelle aimed to make a lasting impact on people's lives and be remembered for making a real difference. As an advanced licensed professional specializing in melanated skin, Mechelle offers a wide range of services, personalized skincare recommendations, and advanced treatments like chemical peels, microneedling, and lasers. Her goal is to provide effective solutions tailored to diverse skin tones, challenging prevailing mindsets that discourage treatment for such skin types. Driven by her dedication to delivering results, Mechelle embarked on creating her own skincare line. Her flagship product, a 1% retinol, stands out for its ability to address multiple skin types and deliver exceptional results. Infused with powerful antioxidants, essential amino acids, minerals, and botanical moisturizers, this retinol promotes healthy cell regeneration and collagen production, resulting in reduced visible signs of aging, diminished pores, and blemishes. Through GLO by ME SKIN, Mechelle Evans is redefining skincare by combining the power of education, quality treatments, and effective products. With her advanced knowledge, personalized approach, and commitment to inclusivity, she has become a trusted advisor and advocate for skin health. In a world where healthy skin is highly valued, Mechelle's vision of empowering individuals to embrace their natural beauty and achieve a healthy complexion is becoming a reality. Her expertise, passion, and transformative results have earned her a reputation as a leading force in the skincare industry. As Mechelle continues to leave her mark on the field, her dedication and expertise are changing lives. Through GLO by ME SKIN, she is making a genuine difference, leaving a lasting legacy as someone who revolutionized skincare and helped individuals achieve radiant, healthy skin. About Mechelle Evans: Mechelle Evans is the founder of GLO by ME SKIN, a skincare brand dedicated to providing innovative and effective skincare solutions. With a passion for skincare and a commitment to education, Mechelle offers personalized services and products to help individuals achieve healthy and radiant skin. Her expertise and transformative results have earned her recognition as a trusted advisor in the skincare industry. Contact Details GLO by ME SKIN Crissy Henry office@9figuremedia.com Company Website http://www.globyme.com/

July 11, 2023 05:24 PM Eastern Daylight Time

Image

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company’s licensee and co-developer in India. NanoViricides has been building out a novel nanomedicine platform for many years, and this platform now includes a pipeline of multiple preclinical antiviral drugs. The Company is developing antiviral medications that are built on the company’s patented nanoviricide technology. Nanomedicine has a lot of promise, but there are almost no nanomedicines available on the market to treat viral infections. Because of prior acquired expertise, NanoViricides’ first-in-class COVID drug, NV-CoV-2, took just about one year to complete IND-enabling studies, from the discovery stage in January 2020. As a small company with a novel mechanism implemented using out-of-the-box technologies, it took the Company much longer time to actually start clinical trials. Now that it has this regulatory experience, additional drug developments should not take such a long lag time. “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, President and Executive Chairman of NanoViricides. NanoViricides’ Treatment Of Coronaviruses The company’s first drug candidate is NV-CoV-2, a broad-spectrum, anti-coronavirus treatment. Other companies have developed treatments for COVID-19, These include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD). However, there are limitations or drawbacks to each of these treatments. As a broad-spectrum anti-coronavirus drug, NV-CoV-2 has been shown to work against a variety of unrelated coronaviruses. This suggests that different strains or mutations are unlikely to escape the drug. Several common coronavirus strains include hCoV-229E, hCoV-OC43, hCoV-HKU1, and hCoV-NL63, which recur seasonally. Of these, NL63 and OC43 present with pneumonia similar to the delta COVID variant in susceptible patients, leading to fatalities at rates that are comparable to seasonal influenza. Now, SARS-CoV-2 with its variants is added to this list as a commonly occurring coronavirus. A Nanomedicine Platform For Other Viruses The trials for NV-CoV-2 are part of the company’s development of a novel platform technology employing nanoviricides. The NV-CoV-2 drug contains NV-387, a first-in-class chemical nanomedicine, and its unique mechanism of action (MoA) doesn’t rely on the patient’s immune system to destroy the virus. The Company says that NV-387 mimics an attachment receptor family to which over 90% of known viruses bind, and NanoViricides hopes that NV-387 will likely be a clinically effective drug against at least a few of these viruses. The Company has said that it has begun R&D work to expand the indications of NV-387 to other viruses. By bringing NV-CoV-2 to human trial, NanoViricides has demonstrated the platform’s capability to deliver a clinically relevant antiviral. After the Phase 1 studies are completed, the safety and tolerability data will be applicable to any other viruses that the Company targets using NV-CoV-2, assuming it can demonstrate pre-clinical success. Then NV-387 can directly enter Phase 2 as an antiviral against such additional viruses — which would likely mean significant cost and time savings for the additional indications, and substantial improvement in the return on investment (ROI) for the Company with commensurate benefits to the investors. The Company is not a “one-trick pony” either. It already has NV-HHV-1, a drug to treat shingles rashes, that has completed pre-clinical studies. The company believes its platform could provide treatments for a host of viruses, including other herpesviruses (cold sores, genital ulcers, and many other serious diseases), as well as influenza and HIV. This would position NanoViricides at the intersection of multiple growing treatment markets. The herpes treatment market was worth $1.5 billion in 2022 and is predicted to grow at a compound annual growth rate (CAGR) of 9.2% over the next seven years. The influenza market is expected to reach $1.2 billion by 2026, while the HIV market is predicted to reach $36 billion by 2027. For now, however, the company is keeping laser-focus on the development of NV-CoV-2 for treating COVID-19 and long COVID. Its current trial will test the drug’s safety and efficacy, and the data will be used to prepare for phase 2 trials. “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations,” said Diwan. “Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.” Learn more about how NanoViricides is tackling different viruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 11, 2023 09:25 AM Eastern Daylight Time

Scancell Holdings "well-financed" and continuing to pursue deals

Scancell Holdings PLC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the clinical stage biopharmaceutical company's progress and financial position. Durrant starts by highlighting that Scancell has "plenty of money" before going into more detail about what's been happening with its two lead compounds, SCIB1 and Modi-1. She also touches on progress in the relationship with Genmab since signing a commercial licensing agreement last year, and clarifies that Scancell is continuing to pursue other such deals: "We've just signed an evaluation with a new company... and we're in current discussions with a second company about another potential deal." She adds that the company is "well financed" with a runway extending into the second half of 2024, but makes it clear that the continued emergence of promising clinical data could make a fundraise necessary - saying that "clearly a company of our size always needs to think about that as we go forward." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 11, 2023 06:51 AM Eastern Daylight Time

Video

MGC Pharmaceuticals "pushing on" after announcing fresh $1mln order

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Thomas Warner from Proactive after the Europe-based plant-inspired medicine company announced it has secured a US$1mln order from AMC Pharma for ArtemiC, an anti-inflammatory that is also shown to provide benefits to Covid sufferers. Clements gives an overview of the order and of the ArtemiC product, explaining that its "the OTC form of CimetrA, which is under development as an FDA new drug indication file." In March 2023, MGC Pharma revealed that ArtemiC had gained a spot on the National Drug Code Database as an OTC Unlicensed Drug, approved by the US FDA. Clements says that "we are pushing on as fast as we can and I think you'll hear more good news about some aspects of one or more of those products in the weeks and months ahead." MGC Pharmaceuticals says on its website that ArtemiC has been tested for safety and efficacy in a double-blind, placebo-controlled clinical trial of 50 patients diagnosed with COVID-19. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 11, 2023 06:23 AM Eastern Daylight Time

Video

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

LONGEVERON INC.

By David Willey, Benzinga Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. The Company, which is now conducting its phase 2a trial, is a clinical-stage biotechnology firm working to develop treatments for rare diseases and age-related and life-threatening conditions. CHDs are the most common congenital disease, affecting around 40,000 babies born in the U.S. every year. While many CHDs can be medically managed, 25% are much more serious and often require immediate surgical intervention. As a result, CHDs are a leading cause of death for infants. An increase in critical CHDs is powering growth in the newborn screening market, which is expected to reach $3 billion in 2031, growing at a compound annual growth rate (CAGR) of 11.2% from 2021 to 2031. Longeveron is working to develop a treatment for one of the most severe CHDs, hypoplastic left heart syndrome (HLHS). HLHS is a very serious heart defect in which the left side of the heart is underdeveloped and unable to provide normal blood circulation through the heart. HLHS accounts for 2-3% of all CHDs, with around 1 in every 3,800 US babies being born with HLHS every year. HLHS is considered a rare pediatric disease, and Longeveron has received a Rare Pediatric Disease Designation from the FDA for Lomecel-B. Children with HLHS require 3 different open-heart surgeries to allow survival, but even with these surgeries, many of the children will go on to need a heart transplant. Despite the increasing sophistication of these surgeries, the neonatal death rate for HLHS is 33%, and the 5-year survival rate is only 50-60%. HLHS treatments are also expensive, costing the average neonatal hospital stay over $280,000. Longeveron Completes Phase 1, Starts Phase 2 Longeveron is focusing on HLHS with its cell-based therapy, the drug candidate, Lomecel-B ™. This drug, which is made from medicinal signaling cells (MSCs), will be a potential combinational therapy delivered via intracardiac injection during the second neonatal open-heart surgery. The goal of adding Lomecel-B ™ is to boost the function of the single ventricle, with the ultimate goal of reducing the need for transplantation and possibly increasing survival. The Company concluded its open-label phase 1 trial on 10 patients, aged four to five months, and followed these children for a period ranging from 3.5-5 years. The one-year trial’s results were published in the European Heart Journal Open, and revealed that all the patients had responded well to the procedure and were transplant-free one year after the treatment. None of the babies experienced a pre-defined safety endpoint, and the procedure was well tolerated. “This data supports our hope that Lomecel-B TM has the potential to alter the treatment landscape for patients with HLHS, a rare and life-threatening congenital heart disease,” said Wa’el Hashad, Longeveron’s Chief Executive Officer. “Notably, the procedure appeared to be generally safe and well-tolerated in the babies undergoing heart surgery in the first 6 months of life. The study provisionally shows suggestions of possible improvement in measures of cardiac function, findings that are presently being tested in our ongoing controlled and randomized Phase 2 study.” Dr. Joshua Hare, who co-authored the European Heart article, is the co-founder of Longeveron and is an established leader in the field of cardiac treatment. He recently published a second article on HLHS, which described the current status of treatments for HLHS and outlined the future direction of the field. The article identifies Lomecel-B ™ as the first-in-class MSC therapy to reach the trial stage. Longeveron is moving forward with its phase 2 trial in partnership with the National Heart, Lung, and Blood Institute and the trial is being conducted at 8 leading pediatric cardiac surgical programs. This randomized, blind, controlled study with 38 patients will evaluate Lomecel-B’s ™ intracardiac injection for both safety and efficacy. Future positive results could position Longeveron as a leader in the field, with the hope of saving the lives of many infants through this novel therapy. Keep up to date with Longeveron’s cell-based therapies on its website www.longeveron.com. We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 844-470-2550 christine@tradigitalir.com Company Website https://longeveron.com/

July 07, 2023 09:00 AM Eastern Daylight Time

NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. NanoViricides (NYSE American: NNVC) is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now active trials into its lead drug candidate, NV-CoV-2. “NV-CoV-2, the Company’s lead drug candidate for the treatment of coronavirus infections including COVID and potentially many cases of long COVID, has entered human clinical trials initiated by the Drug Sponsor Karveer Meditech Pvt. Ltd. India, the Company’s Licensee and co-developer in India,” announced the Company. NanoViricides is developing cutting-edge nanomedicine treatments, which use their special nanomicelles’ ability to directly attack and destroy the virus particles. To do this, the nanoviricides mimick the receptor site on the cell to which the virus binds. No matter how many variants develop, this site remains the same, so the virus is unlikely to escape the nanoviricide drug. The Company’s drug candidate NV-CoV-2 uses the company’s patented nanoviricide platform technology, which uses novel mechanisms to fight COVID-19 and potentially all other human coronaviruses. The Need For A Lasting Coronavirus Treatment As the company races to develop its leading drug, there remains a significant need to develop safe and lasting treatments for COVID-19 and other coronaviruses. It has been estimated that by the end of the four-year period from January 2020 to December 2023, the COVID-19 pandemic will have cost the American economy up to $14 trillion. Furthermore, it is estimated that 65 million people still suffer from “long COVID,” the continuation of coronavirus symptoms for months after clinically the infection itself has subsided. Symptoms of long Covid can range from mild to severe, and the case numbers of those with long Covid are continuing to increase. Could NV-CoV-2 Be Used For Future Pandemics? Then there are the risks of other coronaviruses and future pandemics. A prediction from the disease research group Metabiota, says that there is a 47% - 57% likelihood that another pandemic as serious as COVID-19 could occur within the next 25 years. This is why NanoViricides believes it is important to develop a drug that is safe and effective for treating a wide range of patients. Its drug candidate NV-CoV-2 has oral formulations for milder cases and an injectable solution for more severe patients. The company is focusing its attention on treatment for COVID-19 for now, but the innovative nanomedicine could even be a broad-spectrum antiviral for treating diseases beyond COVID-19. “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, Ph.D., President and Executive Chairman of the Company, explaining, “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations. Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.” Treatments for COVID-19 currently on the market include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD), though there are problems or limitations with each of these options, and the multi-billion-dollar market remains wide open for a new effective treatment. The overall antiviral market is projected to surpass around $71.1 billion by 2032. Learn more about how NanoViricides is tackling coronaviruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 06, 2023 09:00 AM Eastern Daylight Time

1 ... 57 58 59 60 61 ... 197